Completed PHASE2 INTERVENTIONAL 4-arm NCT00701805

Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)

Phase II Study of Paricalcitol Injection Extension Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism

Sponsor: Abbott

Conditions Hemodialysis Secondary Hyperparathyroidism

Interventions Paricalcitol

Updated 7 times since 2017 Last updated: Mar 18, 2011 Started: Jul 31, 2008 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hemodialysis and Secondary Hyperparathyroidism and is currently completed. Abbott leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Abbott Japan Co.,Ltd

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Chiba, Japan , Fukuoka, Japan , Hokkaido, Japan , Ibaraki, Japan , Kanagawa, Japan , Kumamoto, Japan , Nagano, Japan , Nagasaki, Japan , Osaka, Japan and 2 more locations